ClinicalTrials.gg
RecruitingNCT07717307ExtentN1Updated Aug 4, 2026

Study Comparing Limited and Extensive Neck Surgery in Oral Cancer Patients With Neck Spread

An interventional study of Selective Neck Dissection (Levels I-IV) and Modified Neck Dissection (Levels I-V) in Oral Cavity Squamous Cell Carcinoma, sponsored by Kolhapur Cancer Centre - Cancer Centers of America. Recruiting at 1 site in India. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Kolhapur Cancer Centre - Cancer Centers of America · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India — 12 open to participants now, 14 under way, 7 of them phase 3. Squamous Cell Carcinoma of Head and Neck · India.

Planned enrollment
25th of 31
80 · median 224
Started
2026
with 3 others
No phase
6 of 33
4 open now
Primary completion
2031-04
later than 12 of 13 live
Registered
33rd of 33
by date
Lead sponsor
2 of 33
Kolhapur Cancer Centre - Cancer Centers of America

Among the 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India, this one is the 25th largest by planned enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 with no phase, reaches primary completion later than 12 of the 13 other live ones, and was the 33rd registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

12 of the 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India, or all of them as a file.
02

Study summary

Oral cavity squamous cell carcinoma (OCSCC) frequently metastasizes to cervical lymph nodes, and the extent of neck dissection remains an area of ongoing debate in patients with clinically node-positive (cN1) disease. While modified neck dissection (MND, levels I-V) is widely practiced, selective neck dissection (SND, levels I-IV) may provide equivalent oncologic outcomes with reduced surgical morbidity. However, high-quality randomized evidence comparing these approaches is lacking.

The ExteNT N1 Trial is a prospective, randomized, open-label, parallel-group clinical trial designed to compare selective neck dissection (levels I-IV) with modified neck dissection (levels I-V, preserving the spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle) in patients with resectable cN1 oral cavity squamous cell carcinoma. Eligible participants will be randomized in a 1:1 ratio to either treatment arm.

The primary endpoint is 3-year regional recurrence-free survival (RRFS), along with postoperative quality of life measured using the Neck Dissection Impairment Index (NDII). Secondary endpoints include overall survival, disease-free survival, level-wise nodal involvement, nodal yield, shoulder function (Constant-Murley Score, SPADI, and Arm Abduction Score), postoperative complications including chyle leak, and other surgical morbidities.

This trial aims to generate level I evidence regarding the optimal extent of neck dissection for cN1 OCSCC, balancing oncologic safety with preservation of postoperative function and quality of life.

Read the detailed description

Cervical lymph node metastasis is the most important prognostic factor in oral cavity squamous cell carcinoma (OCSCC). Surgical management of the neck is an integral component of treatment; however, the optimal extent of neck dissection for patients with clinically node-positive (cN1) disease remains uncertain. Although modified neck dissection (levels I-V with preservation of non-lymphatic structures) has traditionally been recommended for node-positive disease, several retrospective studies have suggested that carefully selected patients with limited nodal disease may achieve comparable regional control with a less extensive selective neck dissection. Nevertheless, these studies are subject to selection bias, and no adequately powered randomized controlled trial has directly compared these surgical approaches.

Dissection of lower cervical nodal levels may increase operative time and postoperative morbidity, including shoulder dysfunction, sensory deficits, chyle leak, and impairment in quality of life. Reducing the extent of neck dissection without compromising oncologic outcomes could improve postoperative functional recovery and patient-reported outcomes while maintaining regional disease control.

The ExteNT N1 Trial is designed to address this evidence gap by comparing selective neck dissection (levels I-IV) with modified neck dissection (levels I-V) in patients with resectable cN1 OCSCC. In addition to evaluating oncologic outcomes, the study incorporates validated functional and quality-of-life assessments to comprehensively evaluate the impact of the two surgical strategies. Participants will receive standard treatment for the primary tumor, and adjuvant therapy will be administered according to final histopathological findings and contemporary treatment guidelines.

The findings of this trial are expected to provide high-level evidence to guide the surgical management of the clinically N1 neck in OCSCC. If selective neck dissection demonstrates equivalent oncologic outcomes with lower morbidity, it may support a change in surgical practice by reducing unnecessary treatment while preserving function and quality of life.

03

Conditions studied

  • Oral Cavity Squamous Cell Carcinoma

Keywords

  • Oral Cavity Squamous Cell Carcinoma
  • Oral Cancer
  • Head and Neck Cancer
  • Neck Dissection
  • Modified Neck Dissection
  • Cervical Lymph Node Metastasis
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven squamous cell carcinoma of oral cavity will be included
  • Clinical stage T1-T4, N1, M0
  • cN1 neck on clinical examination and imaging (CT/MRI)
  • Single node which is FNAC proven without any other significant nodes.
  • Patients with II and I.
  • Understands the protocol and able to give .

Exclusion criteria

Exclusion Criteria:

  • Recurrent cases
  • Multiple significant nodes
  • Nodes clinical/radiological with ENE
  • Single node at level III/IV/V
  • Single metastatic node with other suspicious nodes
  • Patients with a history of head and neck radiation therapy treatment
  • Previous history of any
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Arm 1- Selective neck dissection level I to level IV

    Participants randomized to this arm will undergo surgical resection of the primary oral cavity squamous cell carcinoma along with ipsilateral selective neck dissection involving cervical lymph node levels I-IV. Contralateral neck management, reconstruction, and adjuvant therapy will be performed according to standard institutional protocols and final histopathological findings.

    Procedure: Selective Neck Dissection (Levels I-IV)

  • Active comparator
    Arm 2- Modified Neck Dissection (Levels I-V)

    Participants randomized to this arm will undergo surgical resection of the primary oral cavity squamous cell carcinoma along with ipsilateral modified neck dissection involving cervical lymph node levels I-V while preserving the spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle whenever oncologically appropriate. Contralateral neck management, reconstruction, and adjuvant therapy will be performed according to standard institutional protocols and final histopathological findings.

    Procedure: Modified Neck Dissection (Levels I-V)

Interventions

  • ProcedureSelective Neck Dissection (Levels I-IV)

    Selective neck dissection will include removal of cervical lymph node levels Ia, Ib, IIa, IIb, III, and IV on the ipsilateral side while preserving uninvolved non-lymphatic structures. The primary oral cavity tumor will be resected according to oncologic principles with reconstruction as required. Contralateral neck management and adjuvant therapy will be provided according to institutional protocols and final histopathological findings.

  • ProcedureModified Neck Dissection (Levels I-V)

    Modified neck dissection will include removal of cervical lymph node levels Ia, Ib, IIa, IIb, III, IV, and V on the ipsilateral side while preserving the spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle whenever oncologically appropriate. The primary oral cavity tumor will be resected according to oncologic principles with reconstruction as required. Contralateral neck management and adjuvant therapy will be provided according to institutional protocols and final histopathological findings.

06

What researchers measure

Primary outcomes

  1. Regional Recurrence-Free Survival (RRFS)

    Regional recurrence-free survival is defined as the time from the date of definitive surgery to the first documented regional recurrence in the cervical lymph nodes or death from any cause, whichever occurs first. Regional recurrence will be confirmed by clinical examination, imaging, and histopathological evaluation whenever feasible.

    Time frame: 3 years after surgery

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from definitive surgery until death from any cause.

    Time frame: Up to 3 years after surgery

  2. Disease-Free Survival (DFS)

    Disease-free survival is defined as the time from definitive surgery to the first documented local, regional, or distant recurrence, or death from any cause.

    Time frame: Up to 3 years after surgery

  3. Level-wise Cervical Lymph Node Metastasis

    Distribution of histopathologically confirmed metastatic lymph nodes according to cervical nodal level.

    Time frame: At the time of surgery (histopathological examination)

  4. Nodal Yield

    Total number of lymph nodes retrieved during neck dissection and confirmed by histopathological examination.

    Time frame: At the time of surgery

  5. Shoulder Function assesment

    Shoulder function will be assessed using the Constant-Murley Score (0-100 points), with higher scores indicating better shoulder function.

    Time frame: Preoperatively; 1 month; 3 months; 6 months, 1 and 2 year

  6. Postoperative Surgical Morbidity

    Incidence of postoperative complications, including chyle leak, hematoma, wound infection, seroma, cranial nerve injury

    Time frame: Within 30 days after surgery

  7. Shoulder function assesment with Shoulder pain and disability index

    Shoulder pain and disability will be assessed using theShoulder pain and disability index questionnaire. Scores range from 0 to 100, with higher scores indicating greater pain and disability.

    Time frame: Preoperatively; 1 week; 1 month; 3 months; 6 months; 1 year; and 2 years after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Pantvaidya GH, Pal P, Vaidya AD, Pai PS, D'Cruz AK. Prospective study of 583 neck dissections in oral cancers: implications for clinical practice. Head Neck. 2014 Oct;36(10):1503-7. doi: 10.1002/hed.23494. Epub 2014 Jan 13. PubMed 23996343 ↗
  • Liang L, Zhang T, Kong Q, Liang J, Liao G. A meta-analysis on selective versus comprehensive neck dissection in oral squamous cell carcinoma patients with clinically node-positive neck. Oral Oncol. 2015 Dec;51(12):1076-81. doi: 10.1016/j.oraloncology.2015.10.005. Epub 2015 Oct 23. PubMed 26500065 ↗
  • Hashmi SS, Abbas A, Bukhari A, Saeed J, Shafqat A, Siddique AH, Buksh AR, Murtaza G. Selective Neck Dissection for Node-Positive Oral Cavity Squamous Cell Carcinoma: A Retrospective Cohort Study. Int Arch Otorhinolaryngol. 2022 Feb 22;26(4):e630-e635. doi: 10.1055/s-0041-1741437. eCollection 2022 Oct. PubMed 36405475 ↗
  • Shin YS, Koh YW, Kim SH, Choi EC. Selective neck dissection for clinically node-positive oral cavity squamous cell carcinoma. Yonsei Med J. 2013 Jan 1;54(1):139-44. doi: 10.3349/ymj.2013.54.1.139. PubMed 23225810 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No individual participant data (IPD) will be shared with other researchers. The study investigators do not have a plan to make de-identified participant-level data publicly available.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Apr 2031, 56 months after the start.

Of 116 non-industry interventional studies with no phase under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 90. This study's planned 56 months is close to that.

Counting every sponsor, half of 127 studies reached it within 59 months; a quarter within 34 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2026
First posted
Jul 21, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Apr 22, 2031
CompletionEst.
Apr 23, 2031
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07717307
Lead sponsor
Kolhapur Cancer Centre - Cancer Centers of America
Responsible party
Maroti Wadewale (Consultant, Head and neck surgical oncology, Kolhapur Cancer Centre - Cancer Centers of America) — Principal investigator
First posted
Jul 21, 2026
Start date
Aug 1, 2026
Primary completion
Apr 22, 2031 (estimated)
Completion
Apr 23, 2031 (estimated)
Last update
Aug 4, 2026

Study contacts

Maroti B Wadewale, MDS, FHNO
Contact
dr.marotiwadewale59@gmail.com
+918483851334
Parag J Watve, MS, FHNS
Contact
paragwatve@kolhapurcancercentre.com
+919823109918

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion